Why the study?
Does Angiopoietin-1 pretreatment of early endothelial outgrowth cells improve renal function in a murine model of acute ischemic kidney injury?
Does Angiopoietin-1 pretreatment of early endothelial outgrowth cells improve renal function in a murine model of acute ischemic kidney injury?
Angiopoietin-1 pretreatment of early endothelial outgrowth cells enhances their renoprotective capacity and reduces renal damage in a murine model of acute ischemic kidney injury.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Ang-1-enhanced cell therapy in murine ischemic AKI; prospective human trials required before clinical consideration.
BACKGROUND: Acute kidney injury (AKI) severely worsens prognosis of hospitalized patients. Early Endothelial Outgrowth Cells act protective in murine acute ischemic renal failure and renoprotective actions of eEOCs have been documented to increase after cell pretreatment with 8-O-cAMP and Melatonin. Angiopoietin-1 is critically involved in maintaining vascular integrity and regeneration. Aim of the study was to analyze the consequences of eEOC treatment with Ang-1 in murine AKI. METHODS: After 40 minutes of unilateral renal artery clamping with contralateral nephrectomy, male C57/Bl6N mice were injected with either untreated or pretreated (Ang-1) syngeneic murine eEOCs. Two days later serum creatinine levels and morphology were evaluated. Cultured, Ang-1 treated murine eEOCs were analyzed for production/release of proangiogenic and proinflammatory mediators, migratory activity, and cell survival, respectively. RESULTS: Angiopoietin-1 pretreatment of eEOCs significantly reduced serum creatinine in cell-injected mice. In vitro analysis showed increased migration of Ang-1 treated eEOCs and supernatant from Ang-1 treated eEOCs stimulated migration of cultured mature endothelial cells. In addition, Ang-1 reduced percentages of Annexin V+/PI+ eEOCs. Intrarenal numbers of eEOCs remained unaffected by Ang-1 and eEOCs did not produce more or less proangiogenic/proinflammatory mediators after being stimulated with Ang-1. CONCLUSIONS: Angiopoietin-1 pretreatment of eEOCs increases the cells' renoprotective competence in ischemic AKI. Thus, the armentarium of eEOC agonists in AKI is increasingly being expanded and the treatment of AKI with eEOCs becomes a promising future option.
No takes yet. Share an insight, caveat, or question.
Patschan et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: